BioMed Research International

BioMed Research International / 2015 / Article
Special Issue

Intelligent Informatics in Translational Medicine

View this Special Issue

Research Article | Open Access

Volume 2015 |Article ID 237969 |

Chien-Jung Chen, Kang-Chiao Tsai, Ping-Hsueh Kuo, Pei-Lin Chang, Wen-Ching Wang, Yung-Jen Chuang, Margaret Dah-Tsyr Chang, "A Heparan Sulfate-Binding Cell Penetrating Peptide for Tumor Targeting and Migration Inhibition", BioMed Research International, vol. 2015, Article ID 237969, 15 pages, 2015.

A Heparan Sulfate-Binding Cell Penetrating Peptide for Tumor Targeting and Migration Inhibition

Academic Editor: Hao-Teng Chang
Received18 Aug 2014
Revised31 Oct 2014
Accepted14 Nov 2014
Published03 May 2015


As heparan sulfate proteoglycans (HSPGs) are known as co-receptors to interact with numerous growth factors and then modulate downstream biological activities, overexpression of HS/HSPG on cell surface acts as an increasingly reliable prognostic factor in tumor progression. Cell penetrating peptides (CPPs) are short-chain peptides developed as functionalized vectors for delivery approaches of impermeable agents. On cell surface negatively charged HS provides the initial attachment of basic CPPs by electrostatic interaction, leading to multiple cellular effects. Here a functional peptide (CPPecp) has been identified from critical HS binding region in hRNase3, a unique RNase family member with in vitro antitumor activity. In this study we analyze a set of HS-binding CPPs derived from natural proteins including CPPecp. In addition to cellular binding and internalization, CPPecp demonstrated multiple functions including strong binding activity to tumor cell surface with higher HS expression, significant inhibitory effects on cancer cell migration, and suppression of angiogenesis in vitro and in vivo. Moreover, different from conventional highly basic CPPs, CPPecp facilitated magnetic nanoparticle to selectively target tumor site in vivo. Therefore, CPPecp could engage its capacity to be developed as biomaterials for diagnostic imaging agent, therapeutic supplement, or functionalized vector for drug delivery.

1. Introduction

Carcinoma is a malignant cancer originating in the ectodermal and endodermal epithelial cells. Interaction between cell surface and microenvironment plays a crucial role in malignant tumor progression. Alterations of cell surface receptor, coreceptor, and adhesive protein expression are reported in various cancer types in vitro and in vivo [13]. Abnormal expression of cell surface molecules notably contributes to enhance tumor cell growth, survival, migration, and invasiveness [4]. Characterization of such alterations and development of novel agent for specific targeting are unmet medical need for early cancer diagnosis.

Glycosaminoglycans (GAGs) including heparan sulfate (HS), chondroitin sulfate (CS), keratan sulfate (KS), or dermatan sulfate (DS) are covalently attached to their core proteins to form proteoglycans. HS proteoglycan (HSPG) present in the extracellular matrix (ECM) provides structural frameworks to mediate cell-cell communication and function in growth factor-receptor binding [5, 6]. HSPGs are key players in modulating tumor progression processes including metastasis, angiogenesis, proliferation, and malignant transformation [4]. Thus, upregulation of cell surface HS may play an active and crucial role in directing malignant phenotype of cancer during different developmental stages.

Cell penetrating peptides (CPPs) are short-chain cationic and/or amphipathic peptides which may be internalized into living cells [7]. CPPs are able to mediate translocation of a conjugated cargo (e.g., anticancer therapeutics) across plasma membrane, providing an effective and nontoxic mechanism for drug delivery [8]. Most CPPs are rich in positively charged Arg and Lys residues and are internalized after initially interacting with cell surface negatively charged GAGs which cluster CPPs on outer membrane surfaces [9, 10].

CPPs might be potentially used in clinical procedures such as gene therapy and cancer therapy [8, 11]. However, most CPPs are unfeasible for in vivo researches due to nonspecificity of their highly cationic characteristics. Cell surface negatively charged HS initializes the contact of CPPs, so particular HS binding CPPs might own mysterious sequence to exert multiple functions including HS binding, cellular binding, lipid binding, and in vivo tissue targeting activities. CPPecp is a recently identified CPP not only binding to negatively charged molecules including GAGs and lipids on cell surface in vitro but also targeting mucosal tissues in vivo [1214]. In this study, we aim to collect and analyze the characteristics of HS-binding cell penetrating peptides derived from natural proteins. Besides, CPPecp itself falling in this classification has demonstrated multiple functions including in vitro tumor binding, tumor migration inhibition and angiogenesis inhibition activities, and in vivo cargo delivery to tumor site. Here, we provide more clues for the design of peptide therapeutics or intratumor delivery strategy by linking of a tumor targeting CPP. Furthermore, CPPecp might be a unique HS probe for cancer diagnosis to facilitate the quality of therapeutic index and molecular imaging in translational medicine.

2. Materials and Methods

2.1. Synthetic Peptides

Peptides CPPecp (NYRWRCKNQN) and EDN32–41 (NYQRRCKNQN) or CPPecp with N-terminally conjugated fluorescein isothiocyanate (FITC) or tetramethylrhodamine (TMR) were synthesized by Genemed Synthesis Inc. and their purities (>90%) were assessed by analytical high-performance liquid chromatography. Peptide sequences were confirmed by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry in Genemed Synthesis Inc.

2.2. Flow Cytometry

Cells (3.0 × 105/well) were added into six-well plates and cultured in the indicated medium. After 24 h, 5 μM FITC-CPPecp dissolved in medium was added into a well and the samples were incubated for 1 h. Cells were then harvested, washed, and suspended in PBS. The fluorescent intensities of the cell samples were measured using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ) and excitation and emission wavelengths of 488 nm and 515–545 nm, respectively. The relative internalization of FITC-CPPecp was reported as the mean fluorescent signal for 10,000 cells.

2.3. Fluorescence Microscopy

CT-26 cells were cultured on coverslips (5.0 × 103/coverslip) in RPMI-1640. After 24 h, cell samples were incubated with FITC or FITC-CPPecp at 37°C for 10 min. Alternatively, CT-26 cells were pretreated with heparinase II ( 2.5 mU/mL) (Sigma-Aldrich, Missouri, USA) at 37°C for 2 h followed by treatment with 5 μM TMR-CPPecp at 37°C for 10 min. The cells were then washed twice with PBS, fixed with 4% (w/v) paraformaldehyde, and rinsed twice with PBS. The coverslips were mounted in a Vectashield antifade mounting medium with DAPI (Vector Labs). Inverted fluorescent microscopy was performed using Axiovert 135 (Carl Zeiss, Göttingen, Germany) to assess the distribution of the FITC-CPPecp or TMR-ECPecp in the cells.

2.4. In Vitro Cell Migration Assay

Effect of CPPecp on cell migration was assessed using a 24-well transwell plate inserted with incorporating polyethylene terephthalate filter membrane with 8 μm pores (BD FalconTM Cell Culture Insert System).

Approximately 4 × 104 CT-26 cells (obtained from ATCC, number: CRL-2638) were suspended in 200 μL of serum-free RPMI-1640 medium (Sigma-Aldrich, Missouri, USA) and pretreated with 1.25, 2.5, 5, and 12.5 μM CPPecp or EDN3241 at RT for 30 min, and then seeded on the upper compartment of transwell insert membrane. The lower compartment of membrane containing 300 μL 1% FBS (Gibco/Invitrogen) RPMI-1640 medium was used as chemoattractant. After incubating at 37°C and 5% CO2 for 18 h, the migrated cells on the lower surface of membrane were fixed with 4% formaldehyde for 15 min and stained with 0.05% crystal violet for 20 min. The nonmigrated cells on the upper surface of membrane were removed by cotton swab. Numbers of migrated cells were counted in a randomly selected microscopic field (100x) using inverted microscopy (Olympus CK40, Artisan Technology Group, Mercury Drive Champaign, USA).

Approximately 5 × 104 human umbilical vein endothelial cells (HUVECs) (obtained from BCRC, number: H-UV001) were suspended in 200 μL complete EC medium (Gibco) containing 0, 5, or 12.5 μM CPPecp and then seeded on the upper compartment of filter. The lower compartment of filter contains 500 μL complete EC medium with 20 ng/mL VEGF (R&D) as stimulator. After incubating at 37°C and 5% CO2 for 4 h, the migrated cells on the lower surface of filter were fixed with 4% formaldehyde at RT for 15 min and stained with Hocechst at RT for 15 min. The nonmigrated cells on the upper surface of filter were removed by cotton swab. Filter membrane of transwell insert was cut down and mounted with Fluoromount mounting medium (Sigma Aldrich, Missouri, USA). Numbers of migrated cells were counted in five randomly selected microscopic fields at magnification 100x using inverted fluorescent microscope (TE2000E, Nikon, Kanagawa, Japan) with a cooled CCD (Evolution VF, MediaCybernetics, Bethesda, MD).

The result was represented as mean ± SD (standard deviation) of three independent experiments. Statistically significant differences were analyzed using unpaired Student’s -test. Asterisks showed level of statistical significance: *; ; *** compared with control.

2.5. Zebrafish Angiogenesis Model

Tg(kdr:EGFP) zebrafish, a well-studied model for vascular embryogenesis [15], was performed to assess the effects of CPPecp on angiogenesis. The Tg(kdr:EGFP) (kindly provided by Dr. Yung-Jen Chuang’s lab at NTHU) is a transgenic zebrafish line that expresses eGFP driven by the kdr promoter in vasculature endothelial cells during zebrafish embryogenesis, which can serve as an in vivo angiogenesis model for drug screening [16]. Fertilized eggs were generated from adult mating pairs and incubated at 28.5°C in a recirculating aquaculture system. The zebrafish embryos were separately injected with 6.3 or 31.5 ng CPPecp (4.6 nL; 4.56 or 22.8 pmol) into yolk sac at 60 h postfertilization (hpf), and PBS injection was set as control (16–20 zebrafish were used for each treatment condition). After incubating for 24 h, development of subintestinal vessels (SIV) pattern in the zebrafish yolk sac was observed and imaged by inverted fluorescent microscope (TE2000E, Nikon, Kanagawa, Japan) with a cooled CCD (Evolution VF, MediaCybernetics, Bethesda, MD).

2.6. Animal Model

All work performed with animals was approved by the Institutional Animal Care and Use Committee at the National Tsing Hua University. Five-week-old female Balb/c mice (supplied by National Laboratory Animal Center, Taiwan) were housed in laboratory animal room at National Tsing Hua University and allowed to adapt to new surrounding for about seven to fourteen days. Animal rooms had a twelve-to-twelve-hour light-dark/day-night cycle and were maintained at constant temperature and humidity. For establishment of tumor-bearing mouse model, CT-26, a mouse colon carcinoma cell was suspended at a density of 1 × 106 cells in 100 μL PBS containing 50% Matrigel (BD Biosciences, San Jose, CA) and subcutaneously injected into the right back of each mouse. Once subcutaneous tumor volumes grew up to 100 mm3, all mice were subjected to various treatments. At the end of the experiment, the mice were sacrificed by CO2 narcosis. All of the organs including kidney, liver, spleen, trachea, lung, intestine, heart, pancreas, stomach, and tumor of these mice were taken, fixed with paraformaldehyde, embedded in paraffin, and sliced into 5 μm tissue slides for Prussian blue staining.

2.7. Magnetic Nanoparticle Conjugated CPPecp and Prussian Blue Staining

To analyze in vivo tissue targeting of CPPecp, we have conjugated CPPecp onto a dextran-coated Fe3O4 type of magnetic nanoparticle (MNP) to form MNP-conjugated CPPecp (MNP-CPPecp) with a mean diameter of 59.3 nm (kindly provided by MagQu. Co., Ltd.) [17]. CT-26 tumor-bearing mouse was utilized to investigate biodistribution of MNP-CPPecp and Prussian blue staining was employed to demonstrate ferric iron in mouse tissues. The CT-26 tumor-bearing mouse was intravenously injected with 150 μL MNP-CPPecp (0.06 emu/g) and sacrificed by CO2 narcosis at a time point of 3, 6, 12, and 24 h after administration. The kidney, heart, liver, spleen, stomach, pancreas, small intestine, large intestine, trachea, lung, and tumor of mice were taken, fixed with paraformaldehyde, embedded in paraffin, and sectioned into 5 μm thick tissue slides, following by deparaffinizing in xylene solution (J. T. Baker Phillipsburg, NJ, USA) and serially rehydrating with 100%, 95%, 85%, 75%, and 50% alcohol. The slides were continuously immersed in working solution (20% hydrochloric acid and 10% potassium ferrocyanide (Sigma, MO, USA) solution mixture, 1 : 1 volume ratio) at room temperature for 30 min and then counterstained with fast nuclear red (Sigma, MO, USA) at RT for 5 min. After dehydration through 95% and 100% alcohol and clearing with xylene, each slide was finally covered with coverslip. Tissue images were digitized using light microscope (Eclipse E400, Nikon) with digital microscopy camera (AxioCam ICc 5, ZEISS).

3. Results and Discussion

3.1. Heparan Sulfate Binding Cell Penetrating Peptides Derived from Natural Proteins

Heparan sulfate (HS) serves as the initial anchoring site for many CPPs through electrostatic interactions between negatively charged sulfates or carboxyl groups and basic amino acids Arg as well as Lys [18]. Till now 27 CPPs from natural proteins including 14 viral protein-derived peptides, 7 animal homeostatic modulator-derived peptides, 3 antimicrobial peptides, and 3 toxin-derived peptides have been demonstrated or predicted to be able to interact with cell surface HS and penetrate cross the plasma membrane. In silico secondary structures of all 27 HS-binding CPPs were predicted by Network Protein Sequence Analysis [19]. As shown in Table 1, 17 peptides including CPPs 2–6, 8–12, 15, and 18–23 exist as α helix (H). Seven peptides including CPPs 1, 7, 13, 14, 16, 17, and 24 form random coil (C). CPP 23 exists as β sheet (E), and CPPs 26 and 27 exist as mixed α helix (H) with β sheet (E) structures. Among 27 CPPs seventeen structures have been validated by in vitro 3D structures deposited in Protein Data Bank (Table 1, underline) [20]. All 14 viral protein-derived CPPs are highly cationic (high pI values) with 10 peptides forming α helix and 4 existing as random coil, penetrating cells through direct translocation [2124] and lipid raft-mediated endocytosis [2529]. Most of the 7 animal homeostatic modulator-derived CPPs may be internalized into cytosol through HS-mediated and energy-dependent endocytosis, among which 5 animal protein-derived peptides are demonstrated to possess either α helix or β sheet to interact with the plasma membrane, while our CPPecp and apolipoprotein B binding domain are unique such that they hold random coil structures in this category. As for 3 antimicrobial peptides, all of them are suggested to interact with cell surface HS and penetrate membrane barrier via energy-dependent endocytosis. LL-37 holds high level of α helix, SynB1 possesses β sheet, and SynB3 retains random coil structures [3032]. For the last category toxin-derived CPPs, bovine prion-derived bPrPp forming α helix and mixed α helix with β strand are distributed in the internal region of venom-derived crotamine, and scorpion toxin-derived maurocalcine [3336].

Peptide name  
Sequence and predicted secondary structure*Heparan sulfate binding regionInternalization mechanismRef.

Viral protein-derived CPP
1TAT peptide (49–57)  
pI: 12.70
RKKRRQRRLipid raft-mediated macropinocytosis[25, 26]
2Nucleoplasmin NLS (155–170)  
pI: 11.47
Not reportedNot reported[58]
3HTLV-II Rex (4–16)  
pI: 12.85
TRRQRTDirect translocation[21, 22]
4Lambda-N (48–62)  
pI: 11.83
RRRERRNot reported[22]
5Phi21 N (12–29)  
pI: 11.45
KTRYKARRANot reported[22]
6Delta N (1–22)   
pI: 11.44
TRRRERRANot reported[22]
7FHV coat (35–49)  
pI: 13.00
8BMV coat (8–26)  
pI: 12.78
ARRNRWNot reported
9HIV-1 Rev (35–46)  
pI: 12.85
RQARRNRRRRWRNot reported[22]
10Rev (26–42)  
pI: 12.54
TRQARRNRRRRWRERQFEnergy dependent lipid raft-mediated macropinocytosis[27, 28]
11CPP from pestivirus envelope glycoprotein (Erns) (194–220)  
pI: 11.72
Basic residuesDirect translocation[23]
12gp41 fusion sequence 
pI: 11.33
WSQPKKKRKVDirect translocation[24]
pI: 12.10
SRPRRPEnergy dependent lipid raft-mediated macropinocytosis[27, 29]
14SV40 NLS 
pI: 11.33
PKKKRKVNot reported[59, 60]

Animal homeostatic modulator-derived CPP
pI: 12.31
NRRMKWDirect translocation 
pI: 10.05
RWRCKMacropinocytosis[12, 62]
17Apolipoprotein B binding domain 
pI: 9.82
Basic residuesEndocytosis[63, 64]
18hCT (932)  
pI: 6.74
Not reportedEndocytosis[63, 65]
pI: 12.48
LRRRIRKMacropinocytosis and clathrin mediated endocytosis[6668]
20hLF peptide 
pI: 10.93
MRKVRGLipid raft-mediated endocytosis[69]
pI: 12.31
NRRMKWKKCaveolae-dependent endocytosis and lipid raft-mediated macropinocytosis[70]

Antimicrobial peptide
22LL-37 (1–37)  
pI: 10.61
FRKSKEKIEndocytosis[30, 31, 71]
23SynB1 (1–18)  
pI: 12.30
Basic residuesEndocytosis[32]
pI: 12.18
Basic residuesEndocytosis[32]

Toxin-derived CPP
25bPrPp (1–28)  
pI: 10.03
Basic residuesMacropinocytosis[33]
26Crotamine (1–42)  
pI: 9.51
27Maurocalcine (MCa) (1–33) 
pI: 9.46
SKKCKR and EKRCRMacropinocytosis[35, 36]

The confidence of the prediction is denoted by scaling the predictions from week (lower-case letter) to strong (upper-case letter). “H,” “E,” and “C” refer to α-helical, β-strand, and random coil propensities, respectively.

Previous researches have shown that the interactions between the positively charged peptide and highly negatively charged membrane components, such as the GAG moieties of cell surface proteoglycans, play a crucial role in the overall process of cellular permeability of highly basic or amphipathic CPPs [37]. Although this investigation may also reflect nonspecific electrostatic interactions between these basic peptides and HS, it has been characterized that negatively charged heparin more effectively blocks uptake of CPPs than other soluble GAGs such as CS and hyaluronic acid [38], likely suggesting that there might be some structural requirements involved in the strong interaction between CPP and HS. In Table 1, 19 of these 27 HS-binding CPPs generally possess conventional heparin binding sequences such as XBBXB and XBBBXXBX where B is a basic amino acid and X represents a random amino acid, and they can also be divided into cationic and amphipathic groups. Most viral factor-derived peptides are basic amino acid-rich. For example, cationic TAT is an extensively used CPP rich in Arg and can interact with sulfated proteoglycans and negatively charged phospholipids on the cell membrane [25]. It should be noted that although 10-amino acid CPPecp is almost equal size to 9-residue TAT and 10-residue SynB3, the features of TAT and SynB3 are quite different from CPPecp. Both TAT derived from viral protein and SynB3 belonging to antimicrobial peptide are highly cationic peptides with high pI values above 12, while our newly identified CPPecp containing only 2 Arg and 1 Lys in a total of 10 amino acids is amphipathic with a pI value of 10.05. Interestingly, the proportion of basic residues in amphipathic crotamine (26%) is close to CPPecp (30%). “RWRCK” motif of CPPecp was previously predicted as a unique functional pattern in all 13 hRNaseA family members employing Reinforced Merging for Unique Segments system (ReMUS) [39]. Another peptide CyLoP-1 (CRWRWKCCKK) derived from crotamine also exhibited efficient intracellular delivery activity. In both cases positively charged residues conducting electrostatic interaction and aromatic Trp exerting transient membrane destabilization were essential to maintain CPP functionality [40, 41]. Taken together, a similar motif  “RWRXK” shown on the loop, where X might be a random amino acid, is present in both CPPecp and crotamine, suggesting that combination of positively charged residues and nonpolar aromatic residues, especially Trp, might provide a design rationale for novel amphipathic cell penetrating peptides.

3.2. Cellular Binding of CPPecp to Tumor Cell with Higher HS Expression Level

Heparan sulfate (HS) is reported to be overexpressed in several tumors [42, 43], while HSPG profiles on different tumor cell surface are largely unclear. Here a mouse colon cancer CT-26 cell line was used for in vitro and in vivo analyses. Cellular binding activity of CPPecp and HS expression level on cell surface of CT-26 cells were accessed for quantitative analysis employing flow cytometry and fluorescent microscopy with fluorescence-labeled CPPecp FITC-CPPecp and an anti-HS monoclonal antibody recognizing an epitope of N-sulfated glucosamine on membrane HS (US Biological, Swampscott, MA, USA). Figure 1(a) showed significant FITC-CPPecp binding activity to CT-26 cells, which correlated well with significantly higher HS expression (Figure 1(b)). In addition, 5 μM FITC-CPPecp rapidly and efficiently internalized into CT-26 cells within 10 min as analyzed by fluorescent microscopy (Figure 1(c)). To further address the importance of HS for CPPecp anchor in the absence of autofluorescence background, removal of cell surface HS by heparinase was carried out along with CPPecp labeled with tetramethylrhodamine (TMR). CT-26 cells were incubated in medium with (+) or without (−) heparinase II for 2 h and then treated with 5 μM TMR-CPPecp for 10 min. TMR-CPPecp rapidly and efficiently bound to CT-26 cell surface (Figure 1(d), upper panel), while removal of cellular HS led to significant reduction in CPPecp attachment (Figure 1(d), lower panel). Taken together, our HS-binding CPPecp possessed strong binding activity to tumor cell surface with higher HS expression, while depletion of cell surface HS abolished such highly selective binding activity of CPPecp to tumor cells.

3.3. Effect of CPPecp on Migration of Mouse Colon Carcinoma Cell

It has been shown that HSPGs may modulate cell migration by interacting with growth factors or chemokines and drives cell migrate toward specific stimuli [44]. Since CPPecp with a novel heparin-binding motif in ECP has already been identified to possess high recognition activity to cellular surface HSPG and penetration activity into cells [12], here whether CPPecp might modulate cancer cell migration through interaction with HSPG was further investigated using in vitro transwell migration assay, while EDN32–41, a 10-amino acid peptide derived from comparable sequence motif of human RNase2 (EDN), possessing a conventional heparin-binding motif was also analyzed as a control. Figure 2 (black bar) showed that migration activity of CT-26 cell was significantly inhibited by CPPecp in a dose-dependent manner such that it decreased to 83%, 71%, 56%, and 54% upon treatment with 1.25, 2.5, 5, and 12.5 μM CPPecp, respectively. Yet treatment with 1.25, 2.5 and 5 μM EDN32–41 could not inhibit migration activity of CT-26 cells, and presence of higher concentration of EDN32–41 (12.5 μM) decreased 33% tumor migration (Figure 2, gray bar). These results indicated that CPPecp containing core RWRCK motif, rather than containing known heparin-binding motif, inhibited CT-26 cell migration across the membrane in vitro. It has been reported that cancer migration was inhibited by antagonism of HS side chains. For example, A5G27 peptide derived from laminin α5 globular domain recognizes HS side-chains of CD44 variant 3 and blocks bioactivity of fibroblast growth factor-2 (FGF-2). It significantly inhibits FGF-2-induced WiDr colon cancer cell migration and invasion [45]. Collectively, inhibitory effect of CPPecp on cancer cell migration is possibly arisen from interaction with cell surface HS.

3.4. Effects of CPPecp on Migration of Vascular Endothelial Cell

Cell surface HS proteoglycan (HSPG) serves as a coreceptor to coordinate binding of vascular endothelial growth factor (VEGF) toward its receptor. It has been reported to be associated with angiogenesis [46, 47]. However, vascular endothelial cell migration is a crucial step in formation of new blood vessel and tumor angiogenesis [48]. To test the hypothesis that CPPecp interacting with cell surface HSPGs also affected angiogenesis, a common model cell line human umbilical vein endothelial cell (HUVEC) was used for in vitro transwell migration assay. Figure 3 indicated that VEGF-induced HUVEC migration was restored by cotreatment with 5 or 12.5 μM CPPecp, leading to, respectively, 77% and 64% migration activity. This result indicated that CPPecp could inhibit VEGF-induced HUVEC migration. Likewise, the CD44-binding peptide A5G27 derived from laminin α5 globular domain inhibits FGF-induced angiogenesis in Chick CAM Assay [49]. Moreover, an HS-binding peptide 6a-P, corresponding to the HSPG binding domain of VEGF, binds to HSPG and affects interaction between VEGF and HSPG [50]. It interferes with angiogenesis by inhibiting VEGF-induced HUVEC migration and binding of VEGF to HUVEC. As a result, involvement of our CPPecp in angiogenesis may be attributed to interaction with cell surface HSPG.

3.5. Effects of CPPecp on Angiogenesis during Embryonic Development of Zebrafish

Cell surface HSPGs serve as a coreceptor to coordinate binding of VEGF toward its receptor and have been reported to be associated with angiogenesis [46, 47]. Tg(kdr:EGFP) zebrafish, a well-studied model for vascular embryogenesis, has been used as model for drug screening and angiogenesis studies [51, 52]. It was thus utilized to investigate CPPecp effects on in vivo embryonic angiogenesis by injecting 4.6 nL of 4.56 or 22.8 pmol CPPecp or PBS (control) into yolk sac of zebrafish at 60 h postfertilization (hpf), and the development of subintestinal vessel (SIV) pattern (Figure 4(a), SIV networks are indicated with red rectangle) at 24 h postinjection (hpi) was monitored with images by inverted fluorescent microscope. Here 16–20 zebrafish were tested for each treatment group. The observed SIV patterns of zebrafish were divided into three groups according to growth level of SIV: normal, mildly inhibited, and severely inhibited phenotypes (Figure 4(b)). In the normal phenotype SIV developed as smooth basket-like pattern with 5-6 arcades. Both mild and severe inhibition phenotypes could be further classified as ectopic SIV pattern, in which SIV exhibited tortuous network and was unable to demonstrate complete basket-like pattern that normal phenotype developed. However, severe inhibition phenotype displayed more incomplete SIV network than mild inhibition phenotype did. In contrast, the zebrafish injected with CPPecp appeared to be tortuous, in which SIV pattern shrank significantly as compared with that of PBS control (Figure 4(c)). Figure 4(d) illustrated quantitative analysis data in which percentage of ectopic SIV phenotype (mildly inhibited phenotype plus severely inhibited phenotype) rose from 39.6% up to 49.2% and 52.6% upon injection with 4.56 and 22.8 pmol CPPecp, respectively. Moreover, severely inhibited SIV phenotype increased from 11.1% up to 26.2% and 32.4% upon injection with 4.56 and 22.8 pmol, respectively. In other words, percentage of severely inhibited phenotype in ectopic phenotype of zebrafish increased from 27.3% (control) up to 52.3% and 60.7% upon injection with 4.56 and 22.8 pmol CPPecp, respectively (Figure 4(e)). These data revealed that our CPPecp possessed antiangiogenesis activity in inhibiting SIV growth of zebrafish. As a result, involvement of CPPecp in angiogenesis may be attributed to interaction with cell surface HS. CPPecp is the first antiangiogenic peptide deciphered in embryonic development of zebrafish.

3.6. Time-Dependent Biodistribution of MNP-CPPecp in CT-26 Tumor-Bearing Mouse

To better understand biodistribution of our HS-binding CPPecp in vivo, CPPecp was conjugated with well-dispersed Fe3O4 magnetic beads (59.3 nm for diameter) to form magnetic nanoparticle-conjugated CPPecp (MNP-CPPecp). CT-26 tumor-bearing mice were intravenously injected with MNP-CPPecp (0.06 emu/g) and sacrificed at different time point after administration (Figure 5(a)). MNP-CPPecp signal was detected using Prussian blue staining to indicate ferric iron in tissue section (blue color). Figure 5(b) indicated that stainable ferric iron (blue color as indicated by yellow arrow) was barely detectable in trachea, heart, and large intestine at all indicated time points, and so did other tissues including stomach, pancreas and kidney (data not shown). The MNP-CPPecp mainly accumulated in liver tissues from 3 h up to 24 h owing to uptake and removal by macrophages of reticuloendothelial system, which played a role in clearance of external substance in liver [53, 54]. Interestingly, Prussian blue staining signals in CT-26 tumor section suggested MNP-CPPecp accumulation from 12 h to 24 h, whereas MNP signal was only detected in liver at 24 h. One recent report showed that exendin-4 peptide-conjugated superparamagnetic iron oxide nanoparticles were inevitably accumulated in liver tissue, suggesting that a nanoparticle might unavoidably be captured by this metabolic organ [55]. However, it is worth noting that CPPecp has potential to target colon carcinoma in vivo, suggesting that CPPecp might be applied for a potent carrier for drug delivery.

3.7. Heparan Sulfate-Binding Cell Penetrating Peptide for Tumor Targeted Strategy

Although CPPs as noninvasive agents have promising biomedical potential for molecular delivery, they are mostly unfeasible for in vivo researches due to nonspecificity of their highly cationic characteristic such as TAT peptide. Due to high uptake rates in vitro and relatively low specificity in vivo of most CPPs, conventional CPPs would be designed for topical applications in CPP-based delivery (Table 1). Further analysis of natural protein-derived CPPs revealed that 5 CPPs exerted in vitro tumor suppression as well as cell internalization activities (Table 2). Although TAT peptide (46–57) demonstrated antiangiogenesis and apoptosis-inducing activities, TAT peptide was proved to show low target specificity in vivo [56]. Distinct from conventional highly cationic CPPs, 4 amphipathic CPPs including CPPecp, crotamine, NFL-TBS (40–63), and p28 peptides demonstrated unique tumor targeting activity in vivo. Even though specific protein receptors for CPPecp and crotamine remain to be investigated, HSPG acting as coreceptor is indispensable for the translocation of CPPecp and crotamine [12, 34]. In addition, both CPPecp and crotamine targeted highly proliferating cells such as tumor tissues [14, 57]. Interestingly, a motif decorating a hydrophilic aromatic amino acid participating in membrane permeation between two arginines (RWR) appeared to be conserved in both CPPecp and crotamine, leading to similar characteristics of these 2 multifunctional HS-binding CPPs. Therefore, amphipathic CPPs might own promising potential to be designed as peptide-based drugs. In particular, HS-binding CPPs are suitable drug carriers for in vivo application in delivery of functional therapeutics.

Name/sequenceFunctionMechanismCell lineTumor mouse modelRef.

CPPecp/NYRWRCKNQNCell penetrating 
HS binding 
Tumor targeting
Block putative HS coreceptor for growth factorCT-26 
Murine colon carcinoma CT-26[1214]

HS binding 
Tumor targeting
Interact with lysosomes to trigger intracellular Ca2+ transients and alter mitochondrial membrane potentialB16F10 
Murine melanoma (B16F10) 
Murine mammary carcinoma (TS/A-pc, TS/A-pc-pGL3)
[34, 57]

Antitumor growth
Inhibit polymerization of microtubulesHuman glioblastoma (T98G) 
Rat glioblastoma (F98) 
Rat gliosarcoma (9L)
Murine glioblastoma (F98)[72, 73]

TAT peptide (46–57)/SYGRKKRRQRRRCell penetrating 
HS binding 
Inhibit VEGF binding to HUVEC and inhibit phosphorylation of ERKHUVEC×[25, 74]

Antitumor growth
Inhibit phosphorylation of VEGFR-2, FAK, and AktHUVECHuman melanoma (UISO-Mel-6)[75]

4. Conclusions

CT-26 colon tumor cells revealed high CPPecp binding activity due to high HSPG expression on cell surface. CPPecp displays not only significantly inhibitory effects on CT-26 cancer migration and angiogenesis in vitro but also antiangiogenesis activity during zebrafish embryogenesis in vivo. Moreover, covalent linkage of CPPecp to magnetic nanoparticle shows potential for in vivo targeting to a subcutaneous CT-26 tumor site. Moreover, CPPecp containing a core RWRXK sequence demonstrates both cell penetrating and epithelial tumor targeting activities. Taken together, our HS-binding CPPecp might be feasible for further application in molecular imaging for tumor homing and selectively targeting drug delivery system.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Chien-Jung Chen and Kang-Chiao Tsai contributed equally to this work.


The authors thank Drs. Ching-Chuan Kuo, Wun-Shaing Wayne Chang, and Yu-Ting Chou for critical comments. This work was supported by National Tsing Hua University (NTHUIOON705IEI and NTHUIOIN205IEI) and National Science Council (NSC101-2622-B-007-001-CC1 and NSC103-2325-B-007-002) to M. D.-T. Chang. C.-J. Chen and P.-H. Kuo are awarded a scholarship sponsored by Apex Biotechnology Corporation, Taiwan. K.-C. Tsai is supported by Graduate Program of Biotechnology in Medicine sponsored by National Tsing Hua University and National Health Research Institute in Taiwan.


  1. K. R. Kampen, “The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology,” Anti-Cancer Drugs, vol. 23, no. 4, pp. 347–354, 2012. View at: Publisher Site | Google Scholar
  2. R. Sasisekharan, Z. Shriver, G. Venkataraman, and U. Narayanasami, “Roles of heparan-sulphate glycosaminoglycans in cancer,” Nature Reviews Cancer, vol. 2, no. 7, pp. 521–528, 2002. View at: Publisher Site | Google Scholar
  3. M. Adachi, T. Taki, M. Higashiyama, N. Kohno, H. Inufusa, and M. Miyake, “Significance of integrin α5 gene expression as a prognostic factor in node-negative non-small cell lung cancer,” Clinical Cancer Research, vol. 6, no. 1, pp. 96–101, 2000. View at: Google Scholar
  4. E. H. Knelson, J. C. Nee, and G. C. Blobe, “Heparan sulfate signaling in cancer,” Trends in Biochemical Sciences, vol. 39, no. 6, pp. 277–288, 2014. View at: Publisher Site | Google Scholar
  5. A. Ori, M. C. Wilkinson, and D. G. Fernig, “A systems biology approach for the investigation of the heparin/heparan sulfate interactome,” The Journal of Biological Chemistry, vol. 286, no. 22, pp. 19892–19904, 2011. View at: Publisher Site | Google Scholar
  6. N. Sasaki, N. Higashi, T. Taka, M. Nakajima, and T. Irimura, “Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate,” The Journal of Immunology, vol. 172, no. 6, pp. 3830–3835, 2004. View at: Publisher Site | Google Scholar
  7. J. Regberg, A. Srimanee, and Ü. Langel, “Applications of cell-penetrating peptides for tumor targeting and future cancer therapies,” Pharmaceuticals, vol. 5, no. 9, pp. 991–1007, 2012. View at: Publisher Site | Google Scholar
  8. V. Kersemans, K. Kersemans, and B. Cornelissen, “Cell penetrating peptides for in vivo molecular imaging applications,” Current Pharmaceutical Design, vol. 14, no. 24, pp. 2415–2427, 2008. View at: Publisher Site | Google Scholar
  9. S. Console, C. Marty, C. García-Echeverría, R. Schwendener, and K. Ballmer-Hofer, “Antennapedia and HIV transactivator of transcription (TAT) “protein transduction domains” promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans,” The Journal of Biological Chemistry, vol. 278, no. 37, pp. 35109–35114, 2003. View at: Publisher Site | Google Scholar
  10. S. Deshayes, T. Plénat, P. Charnet, G. Divita, G. Molle, and F. Heitz, “Formation of transmembrane ionic channels of primary amphipathic cell-penetrating peptides. Consequences on the mechanism of cell penetration,” Biochimica et Biophysica Acta, vol. 1758, no. 11, pp. 1846–1851, 2006. View at: Publisher Site | Google Scholar
  11. B. G. Bitler and J. A. Schroeder, “Anti-cancer therapies that utilize cell penetrating peptides,” Recent Patents on Anti-Cancer Drug Discovery, vol. 5, no. 2, pp. 99–108, 2010. View at: Google Scholar
  12. S.-L. Fang, T.-C. Fan, H.-W. Fu et al., “A novel cell-penetrating peptide derived from human eosinophil cationic protein,” PLoS ONE, vol. 8, no. 3, Article ID e57318, 2013. View at: Publisher Site | Google Scholar
  13. P.-C. Lien, P.-H. Kuo, C.-J. Chen et al., “In silico prediction and in vitro characterization of multifunctional human RNase3,” BioMed Research International, vol. 2013, Article ID 170398, 12 pages, 2013. View at: Publisher Site | Google Scholar
  14. C.-J. Chen, P.-H. Kuo, T.-J. Hung et al., “In vitro characterization and in vivo application of a dual functional peptide,” in Proceedings of the 7th International Conference on Complex, Intelligent, and Software Intensive Systems (CISIS '13), pp. 576–581, Taichung, Taiwan, July 2013. View at: Publisher Site | Google Scholar
  15. K. R. Kidd and B. M. Weinstein, “Fishing for novel angiogenic therapies,” British Journal of Pharmacology, vol. 140, no. 4, pp. 585–594, 2003. View at: Publisher Site | Google Scholar
  16. G. N. Serbedzija, E. Flynn, and C. E. Willett, “Zebrafish angiogenesis: a new model for drug screening,” Angiogenesis, vol. 3, no. 4, pp. 353–359, 1999. View at: Publisher Site | Google Scholar
  17. S. Y. Yang, J. L. Wu, C. H. Tso et al., “A novel quantitative immunomagnetic reduction assay for Nervous necrosis virus,” Journal of Veterinary Diagnostic Investigation, vol. 24, no. 5, pp. 911–917, 2012. View at: Publisher Site | Google Scholar
  18. I. Capila and R. J. Linhardt, “Heparin-protein interactions,” Angewandte Chemie—International Edition, vol. 41, no. 3, pp. 391–412, 2002. View at: Google Scholar
  19. C. Combet, C. Blanchet, C. Geourjon, and G. Deléage, “NPS@: network protein sequence analysis,” Trends in Biochemical Sciences, vol. 25, no. 3, pp. 147–150, 2000. View at: Publisher Site | Google Scholar
  20. J. L. Sussman, E. E. Abola, D. Lin, J. Jiang, N. O. Manning, and J. Prilusky, “The protein data bank: Bridging the gap between the sequence and 3D structure world,” Genetica, vol. 106, no. 1-2, pp. 149–158, 1999. View at: Publisher Site | Google Scholar
  21. Y. G. Choi and A. L. N. Rao, “Molecular studies on bromovirus capsid protein: VII. Selective packaging of BMV RNA4 by specific N-terminal arginine residues,” Virology, vol. 275, no. 1, pp. 207–217, 2000. View at: Publisher Site | Google Scholar
  22. S. Futaki, T. Suzuki, W. Ohashi et al., “Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery,” Journal of Biological Chemistry, vol. 276, no. 8, pp. 5836–5840, 2001. View at: Publisher Site | Google Scholar
  23. J. P. M. Langedijk, “Translocation activity of C-terminal domain of pestivirus Erns and ribotoxin L3 loop,” Journal of Biological Chemistry, vol. 277, no. 7, pp. 5308–5314, 2002. View at: Publisher Site | Google Scholar
  24. L. Chaloin, P. Vidal, P. Lory et al., “Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties,” Biochemical and Biophysical Research Communications, vol. 243, no. 2, pp. 601–608, 1998. View at: Publisher Site | Google Scholar
  25. E. Vivès, P. Brodin, and B. Lebleu, “A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus,” Journal of Biological Chemistry, vol. 272, no. 25, pp. 16010–16017, 1997. View at: Publisher Site | Google Scholar
  26. J. S. Wadia, R. V. Stan, and S. F. Dowdy, “Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis,” Nature Medicine, vol. 10, no. 3, pp. 310–315, 2004. View at: Publisher Site | Google Scholar
  27. T. Sugita, T. Yoshikawa, Y. Mukai et al., “Comparative study on transduction and toxicity of protein transduction domains,” British Journal of Pharmacology, vol. 153, no. 6, pp. 1143–1152, 2008. View at: Publisher Site | Google Scholar
  28. S. Kameyama, M. Horie, T. Kikuchi et al., “Acid wash in determining cellular uptake of fab/cell-permeating peptide conjugates,” Biopolymers, vol. 88, no. 2, pp. 98–107, 2007. View at: Publisher Site | Google Scholar
  29. G. Elliott and P. O'Hare, “Intercellular trafficking and protein delivery by a herpesvirus structural protein,” Cell, vol. 88, no. 2, pp. 223–233, 1997. View at: Publisher Site | Google Scholar
  30. F. J. Byfield, Q. Wen, K. Leszczyńska et al., “Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability,” The American Journal of Physiology—Cell Physiology, vol. 300, no. 1, pp. C105–C112, 2011. View at: Publisher Site | Google Scholar
  31. S. Pochet, S. Tandel, S. Querriére et al., “Modulation by LL-37 of the responses of salivary glands to purinergic agonists,” Molecular Pharmacology, vol. 69, no. 6, pp. 2037–2046, 2006. View at: Publisher Site | Google Scholar
  32. G. Drin, S. Cottin, E. Blanc, A. R. Rees, and J. Temsamani, “Studies on the internalization mechanism of cationic cell-penetrating peptides,” The Journal of Biological Chemistry, vol. 278, no. 33, pp. 31192–31201, 2003. View at: Publisher Site | Google Scholar
  33. M. Magzoub, S. Sandgren, P. Lundberg et al., “N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis,” Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 379–385, 2006. View at: Publisher Site | Google Scholar
  34. F. D. Nascimento, M. A. F. Hayashi, A. Kerkis et al., “Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans,” The Journal of Biological Chemistry, vol. 282, no. 29, pp. 21349–21360, 2007. View at: Publisher Site | Google Scholar
  35. Z. Fajloun, R. Kharrat, L. Chen et al., “Chemical synthesis and characterization of maurocalcine, a scorpion toxin that activates Ca2+ release channel/ryanodine receptors,” FEBS Letters, vol. 469, no. 2-3, pp. 179–185, 2000. View at: Publisher Site | Google Scholar
  36. A. Mosbah, R. Kharrat, Z. Fajloun et al., “A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel,” Proteins, vol. 40, no. 3, pp. 436–442, 2000. View at: Publisher Site | Google Scholar
  37. E. Vives, “Cellular utake of the Tat peptide: an endocytosis mechanism following ionic interactions,” Journal of Molecular Recognition, vol. 16, no. 5, pp. 265–271, 2003. View at: Publisher Site | Google Scholar
  38. M. Tyagi, M. Rusnati, M. Presta, and M. Giacca, “Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans,” The Journal of Biological Chemistry, vol. 276, no. 5, pp. 3254–3261, 2001. View at: Publisher Site | Google Scholar
  39. T.-W. Pai, M. D.-T. Chang, W.-S. Tzou et al., “REMUS: a tool for identification of unique peptide segments as epitopes,” Nucleic Acids Research, vol. 34, pp. W198–W201, 2006. View at: Publisher Site | Google Scholar
  40. D. Jha, R. Mishra, S. Gottschalk et al., “CyLoP-1: a novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes,” Bioconjugate Chemistry, vol. 22, no. 3, pp. 319–328, 2011. View at: Publisher Site | Google Scholar
  41. G. Dom, C. Shaw-Jackson, C. Matis et al., “Cellular uptake of Antennapedia Penetratin peptides is a two-step process in which phase transfer precedes a tryptophan-dependent translocation,” Nucleic Acids Research, vol. 31, no. 2, pp. 556–561, 2003. View at: Publisher Site | Google Scholar
  42. H. Park, Y. Kim, Y. Lim, I. Han, and E.-S. Oh, “Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells,” The Journal of Biological Chemistry, vol. 277, no. 33, pp. 29730–29736, 2002. View at: Publisher Site | Google Scholar
  43. K. Nackaerts, E. Verbeken, G. Deneffe, B. Vanderschueren, M. Demedts, and G. David, “Heparan sulfate proteoglycan expression in human lung-cancer cells,” International Journal of Cancer, vol. 74, no. 3, pp. 335–345, 1997. View at: Google Scholar
  44. R. D. Sanderson, “Heparan sulfate proteoglycans in invasion and metastasis,” Seminars in Cell and Developmental Biology, vol. 12, no. 2, pp. 89–98, 2001. View at: Publisher Site | Google Scholar
  45. S. Hibino, M. Shibuya, M. P. Hoffman et al., “Laminin α5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44,” Cancer Research, vol. 65, no. 22, pp. 10494–10501, 2005. View at: Publisher Site | Google Scholar
  46. M. M. Fuster, L. Wang, J. Castagnola et al., “Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis,” The Journal of Cell Biology, vol. 177, no. 3, pp. 539–549, 2007. View at: Publisher Site | Google Scholar
  47. L. Jakobsson, J. Kreuger, K. Holmborn et al., “Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis,” Developmental Cell, vol. 10, no. 5, pp. 625–634, 2006. View at: Publisher Site | Google Scholar
  48. L. Lamalice, F. Le Boeuf, and J. Huot, “Endothelial cell migration during angiogenesis,” Circulation Research, vol. 100, no. 6, pp. 782–794, 2007. View at: Publisher Site | Google Scholar
  49. S. Hibino, M. Shibuya, J. A. Engbring, M. Mochizuki, M. Nomizu, and H. K. Kleinman, “Identification of an active site on the laminin α5 chain globular domain that binds to CD44 and inhibits malignancy,” Cancer Research, vol. 64, no. 14, pp. 4810–4816, 2004. View at: Publisher Site | Google Scholar
  50. T.-Y. Lee, J. Folkman, and K. Javaherian, “HSPG-Binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in Murine model,” PLoS ONE, vol. 5, no. 4, Article ID e9945, 2010. View at: Publisher Site | Google Scholar
  51. S. Nicoli, G. De Sena, and M. Presta, “Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 2061–2068, 2009. View at: Publisher Site | Google Scholar
  52. M.-W. Kuo, C.-H. Wang, H.-C. Wu, S.-J. Chang, and Y.-J. Chuang, “Soluble THSD7A is an N-glycoprotein that promotes endothelial cell migration and tube formation in angiogenesis,” PLoS ONE, vol. 6, no. 12, Article ID e29000, 2011. View at: Publisher Site | Google Scholar
  53. R. Kumar, I. Roy, T. Y. Ohulchanskky et al., “In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles,” ACS Nano, vol. 4, no. 2, pp. 699–708, 2010. View at: Publisher Site | Google Scholar
  54. S. Nagayama, K.-I. Ogawara, Y. Fukuoka, K. Higaki, and T. Kimura, “Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics,” International Journal of Pharmaceutics, vol. 342, no. 1-2, pp. 215–221, 2007. View at: Publisher Site | Google Scholar
  55. B. Zhang, B. Yang, C. Zhai, B. Jiang, and Y. Wu, “The role of exendin-4-conjugated superparamagnetic iron oxide nanoparticles in beta-cell-targeted MRI,” Biomaterials, vol. 34, no. 23, pp. 5843–5852, 2013. View at: Publisher Site | Google Scholar
  56. D. Sarko, B. Beijer, R. G. Boy et al., “The pharmacokinetics of cell-penetrating peptides,” Molecular Pharmaceutics, vol. 7, no. 6, pp. 2224–2231, 2010. View at: Publisher Site | Google Scholar
  57. F. D. Nascimento, L. Sancey, A. Pereira et al., “The natural cell-penetrating peptide crotamine targets tumor tissue in vivo and triggers a lethal calcium-dependent pathway in cultured cells,” Molecular Pharmaceutics, vol. 9, no. 2, pp. 211–221, 2012. View at: Publisher Site | Google Scholar
  58. D. Görlich and I. W. Mattaj, “Nucleocytoplasmic transport,” Science, vol. 271, no. 5255, pp. 1513–1518, 1996. View at: Publisher Site | Google Scholar
  59. D. Kalderon, B. L. Roberts, W. D. Richardson, and A. E. Smith, “A short amino acid sequence able to specify nuclear location,” Cell, vol. 39, no. 3, pp. 499–509, 1984. View at: Publisher Site | Google Scholar
  60. D. A. Jans, D. A. Jans, P. Jans, and P. Jans, “Negative charge at the casein kinase II site flanking the nuclear localization signal of the SV40 large T-antigen is mechanistically important for enhanced nuclear import,” Oncogene, vol. 9, no. 10, pp. 2961–2968, 1994. View at: Google Scholar
  61. D. Derossi, A. H. Joliot, G. Chassaing, and A. Prochiantz, “The third helix of the Antennapedia homeodomain translocates through biological membranes,” The Journal of Biological Chemistry, vol. 269, no. 14, pp. 10444–10450, 1994. View at: Google Scholar
  62. T.-C. Fan, H.-T. Chang, I.-W. Chen, H.-Y. Wang, and M. D.-T. Chang, “A heparan sulfate-facilitated and raft-dependent macropinocytosis of eosinophil cationic protein,” Traffic, vol. 8, no. 12, pp. 1778–1795, 2007. View at: Publisher Site | Google Scholar
  63. M. C. Schmidt, B. Rothen-Rutishauser, B. Rist et al., “Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane,” Biochemistry, vol. 37, no. 47, pp. 16582–16590, 1998. View at: Publisher Site | Google Scholar
  64. N. Sakamoto and A. S. Rosenberg, “Apolipoprotein B binding domains: evidence that they are cell-penetrating peptides that efficiently deliver antigenic peptide for cross-presentation of cytotoxic T cells,” Journal of Immunology, vol. 186, no. 8, pp. 5004–5011, 2011. View at: Publisher Site | Google Scholar
  65. S. Lang, B. Rothen-Rutishauser, J. C. Perriard, M. C. Schmidt, and H. P. Merkle, “Permeation and pathways of human calcitonin (hCT) across excised bovine nasal mucosa,” Peptides, vol. 19, no. 3, pp. 599–607, 1998. View at: Publisher Site | Google Scholar
  66. A. Elmquist, M. Lindgren, T. Bartfai, and Ü. Langel, “Ve-cadherin-derived cell-penetrating peptide, pVEC with carrier functions,” Experimental Cell Research, vol. 269, no. 2, pp. 237–244, 2001. View at: Publisher Site | Google Scholar
  67. E. Eiríksdóttir, I. Mäger, T. Lehto, S. El Andaloussi, and Ü. Langel, “Cellular internalization kinetics of (luciferin-)cell-penetrating peptide conjugates,” Bioconjugate Chemistry, vol. 21, no. 9, pp. 1662–1672, 2010. View at: Publisher Site | Google Scholar
  68. I. Mäger, E. Eiríksdóttir, K. Langel, S. EL Andaloussi, and Ü. Langel, “Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay,” Biochimica et Biophysica Acta, vol. 1798, no. 3, pp. 338–343, 2010. View at: Publisher Site | Google Scholar
  69. F. Duchardt, I. R. Ruttekolk, W. P. R. Verdurmen et al., “A cell-penetrating peptide derived from human lactoferrin with conformation-dependent uptake efficiency,” The Journal of Biological Chemistry, vol. 284, no. 52, pp. 36099–36108, 2009. View at: Publisher Site | Google Scholar
  70. H. Noguchi, S. Matsumoto, T. Okitsu et al., “PDX-1 protein is internalized by lipid raft-dependent macropinocytosis,” Cell Transplantation, vol. 14, no. 9, pp. 637–645, 2005. View at: Publisher Site | Google Scholar
  71. F. J. Byfield, Q. Wen, K. Leszczyńska et al., “Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability,” American Journal of Physiology—Cell Physiology, vol. 300, no. 1, pp. C105–C112, 2011. View at: Publisher Site | Google Scholar
  72. R. Berges, J. Balzeau, A. C. Peterson, and J. Eyer, “A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis,” Molecular Therapy, vol. 20, no. 7, pp. 1367–1377, 2012. View at: Publisher Site | Google Scholar
  73. C. Lépinoux-Chambaud and J. Eyer, “The NFL-TBS.40–63 anti-glioblastoma peptide enters selectively in glioma cells by endocytosis,” International Journal of Pharmaceutics, vol. 454, no. 2, pp. 738–747, 2013. View at: Publisher Site | Google Scholar
  74. H. Jia, M. Lohr, S. Jezequel et al., “Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis,” Biochemical and Biophysical Research Communications, vol. 283, no. 2, pp. 469–479, 2001. View at: Publisher Site | Google Scholar
  75. R. R. Mehta, T. Yamada, B. N. Taylor et al., “A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt,” Angiogenesis, vol. 14, no. 3, pp. 355–369, 2011. View at: Publisher Site | Google Scholar

Copyright © 2015 Chien-Jung Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.